Reducing POM to P headaches
October 12, 2005Sales and Marketing
Following an eight-week period of public consultation, the Committee on Safety of Medicines is to shortly advise health ministers about …
Creative Lynx to work on Novartis transplantation brands
October 12, 2005Medical Communications
Novartis has awarded advertising accounts for its ophthalmology and transplantation portfolios to Manchester-based advertising agency Creative Lynx.The pharma company held …
GPs need pharma expertise
October 5, 2005GPs are calling out for pharmaceutical companies to provide them with management skills as they take on a new role …
Resolute selected for IBD campaign
October 3, 2005Medical Communications
Procter & Gamble has chosen Resolute Communications to conduct a combined PR and medical education programme for its inflammatory bowel …
Pharma cast as ‘bad guys’ in Hollywood blockbuster
September 30, 2005Sales and Marketing
A new Hollywood thriller featuring the pharmaceutical industry as the 'bad guys' is to hit UK screens next week.The Constant …
Genzyme opens first European research centre in Cambridge
September 30, 2005Research and Development
Genzyme, one of the most successful US biotech companies, has opened its first European research centre in Cambridge, UK – …
Davis to leave Takeda UK
September 30, 2005Sales and Marketing
Andy Davis, the high-profile managing director of Takeda UK is to leave the company.Davis is best known for overseeing a …
New leader for FDA in turmoil
September 30, 2005Sales and Marketing
Andrew von Eschenbach has been appointed the new acting head of the FDA after the surprise resignation of Lester Crawford.Crawford …
NICE seeks urgent fix for slow appraisals
September 29, 2005Sales and Marketing
Patients waiting for access to new, more effective medicines could be prescribed them earlier if new proposals are adopted.NICE, the …
The inspector calls
September 28, 2005Research and Development
I have become a pharmacovigilance bore within my company, a prophet of doom. It is worse than that, because for …
Astellas launches Flomaxtra XL
September 27, 2005Sales and Marketing
Astellas has launched Flomaxtra XL, a new treatment for the symptoms of BPH or benign prostatic hyperplasia.The condition is the …
Lilly increasing investment in UK R&D
September 23, 2005Research and Development
Lilly has opened a new £26 million UK research facility, a move which underlines its commitment to developing medicines in …
Novartis pipeline promises cardiovascular advances
September 22, 2005Research and Development
Novartis hopes to expand its presence in cardiovascular medicine with the filing next year of two potentially first-in-class products with …
US rejects Pfizer’s injectable Cox-II
September 22, 2005Sales and Marketing
The FDA has denied approval for Pfizer's injectable pain drug Dynastat, delivering a fresh blow to the embattled Cox-II class …
NICE to review guidance on hypertension treatments
September 22, 2005Research and Development
NICE has set up a specialist advisory group to review new data which could lead to thousands of heart patients …
New data gives Seretide upper hand in respiratory battle
September 20, 2005Sales and Marketing
Seretide's domination in the global respiratory market looks set to be bolstered by a new head to head study with …
Biotechs back change to UK pricing system
September 16, 2005The current UK medicines pricing system discriminates against smaller biotech companies, and should be altered to take this into account, …
New NHS leaders in Alzheimer’s research and development
September 15, 2005A new NHS team has been set up to accelerate the development of new medical treatments for neurodegenerative conditions such …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
